Thrombocytosis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 63: | Line 63: | ||
* Vascular occlusive events and [[Bleeding|hemorrhages]] | * Vascular occlusive events and [[Bleeding|hemorrhages]] | ||
| align="center" style="background:#F5F5F5;" + |± | | align="center" style="background:#F5F5F5;" + |± | ||
| align="center" style="background:#F5F5F5;" + |Flushing | | align="center" style="background:#F5F5F5;" + | | ||
* Flushing | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
Line 107: | Line 108: | ||
* Ashkenazi Jewish descent | * Ashkenazi Jewish descent | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |Facial plethora | | align="center" style="background:#F5F5F5;" + | | ||
* Facial plethora | |||
| align="center" style="background:#F5F5F5;" + |± | | align="center" style="background:#F5F5F5;" + |± | ||
| align="center" style="background:#F5F5F5;" + |Nl | | align="center" style="background:#F5F5F5;" + |Nl | ||
Line 148: | Line 150: | ||
* Chemicals exposure | * Chemicals exposure | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + |[[Pallor]] | | align="center" style="background:#F5F5F5;" + | | ||
* [[Pallor]] | |||
* [[Bruising]] | * [[Bruising]] | ||
* [[Nodules|Skin nodules]] | * [[Nodules|Skin nodules]] | ||
Line 508: | Line 512: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* History of close contact | * History of close contact | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Acutely ill | * Acutely ill | ||
Line 542: | Line 546: | ||
| align="center" style="background:#F5F5F5;" + |Any | | align="center" style="background:#F5F5F5;" + |Any | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Family history of | * Family history of rheumatologic isorders | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Acutely ill | |||
| align="center" style="background:#F5F5F5;" + | + | |||
| align="center" style="background:#F5F5F5;" + |Nl | |||
| align="center" style="background:#F5F5F5;" + |- | |||
| align="center" style="background:#F5F5F5;" + |- | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* [[Arthritis]] | |||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Microcytic anemia | |||
* [[Myelofibrosis|Megakaryocytic]] fragments | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Proliferation of [[Megakaryocyte|megakaryocytes]] | |||
| align="center" style="background:#F5F5F5;" + |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" + |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Depends on the type | |||
| align="center" style="background:#F5F5F5;" + |Clinical manifestation+ culture | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Depends on the type | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Acute pancreatitis]] | ! align="center" style="background:#DCDCDC;" + |[[Acute pancreatitis]] | ||
Line 569: | Line 580: | ||
| align="center" style="background:#F5F5F5;" + | - | | align="center" style="background:#F5F5F5;" + | - | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |Any | | align="center" style="background:#F5F5F5;" + |Any | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* [[Long-term effects of alcohol|Alcohol consumption]] | * [[Long-term effects of alcohol|Alcohol consumption]] | ||
* [[Gallstone disease|Gallstone]] | * [[Gallstone disease|Gallstone]] | ||
* [[Hyperlipoproteinemia|Hypertriglyceridemia]] | * [[Hyperlipoproteinemia|Hypertriglyceridemia]] | ||
* [[Obesity]] | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 582: | Line 594: | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Abdominal tenderness | * [[Tenderness (medicine)|Abdominal tenderness]] | ||
* N/V | * [[Nausea and vomiting|N/V]] | ||
* [[Dyspnea]] | |||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
Line 594: | Line 607: | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↑ | | align="center" style="background:#F5F5F5;" + |Nl to ↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Diffusely enlarged and hypoechoic [[pancreas]] on abdominal [[ultrasound]] | |||
* Focal or diffuse enlargement of the [[pancreas]] with heterogeneous enhancement on abdominal [[Computed tomography|CT scan]] | |||
| align="center" style="background:#F5F5F5;" + |Clinical manifestation | | align="center" style="background:#F5F5F5;" + |Clinical manifestation | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Rarely progress to severe [[inflammation]] and [[necrosis]] | |||
* '''Organ failure''' | |||
|- | |- | ||
! align="center" style="background:#DCDCDC;" |[[Cancer|Malignancy]] | ! align="center" style="background:#DCDCDC;" |[[Cancer|Malignancy]]<ref name="YangJiang2018">{{cite journal|last1=Yang|first1=Chen|last2=Jiang|first2=Hui|last3=Huang|first3=Shaozhuo|last4=Hong|first4=Hui|last5=Huang|first5=Xiaowen|last6=Wang|first6=Xiaojie|last7=Liao|first7=Weixin|last8=Wang|first8=Xueyi|last9=Chen|first9=Xuewen|last10=Jiang|first10=Liming|title=The prognostic role of pretreatment thrombocytosis in gastric cancer|journal=Medicine|volume=97|issue=31|year=2018|pages=e11763|issn=0025-7974|doi=10.1097/MD.0000000000011763}}</ref> | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Proliferation of [[Megakaryocyte|megakaryocytes]] | |||
* Accelerated [[platelet]] release | |||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | - | |||
| align="center" style="background:#F5F5F5;" + |± | |||
| align="center" style="background:#F5F5F5;" + |± | |||
| align="center" style="background:#F5F5F5;" + |Any | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Prior malignancy | |||
* Exposure to chemicals | |||
* Family history of malignancy | |||
| align="center" style="background:#F5F5F5;" + |+ | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Cachectic | |||
| align="center" style="background:#F5F5F5;" + | - | |||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | |||
| align="center" style="background:#F5F5F5;" + |Depends on the type | |||
| align="center" style="background:#F5F5F5;" + | - | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Tenderness | |||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + |↑ | | align="center" style="background:#F5F5F5;" + |↑ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Microcytic anemia | |||
* [[Myelofibrosis|Megakaryocytic]] fragments | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Proliferation of [[Megakaryocyte|megakaryocytes]] | |||
| align="center" style="background:#F5F5F5;" + |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" + |Nl to ↑ | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Depends on the type | |||
| align="center" style="background:#F5F5F5;" + |[[Biopsy]] | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Potential effective predictor of overall survival | |||
* [[Venous thromboembolism]] | |||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition |
Revision as of 16:49, 31 August 2018
Thrombocytosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Thrombocytosis differential diagnosis On the Web |
American Roentgen Ray Society Images of Thrombocytosis differential diagnosis |
Risk calculators and risk factors for Thrombocytosis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Thrombocytosis Differential Diagnosis
Differentiating the diseases that can cause thrombocytosis :
Category | Condition | Etiology | Mechanism | Inherited | Acquried | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | ||||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||||||
Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other | CBC | PBS | Bone marrow exam | PT | PTT | ||||||||||||||||
Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Plt | HB | WBC | ||||||||||||||||||||||
Autonomous thrombocytosis | Hematologic malignancies | Essential thrombocythemia[1] |
|
+ | - | - | - | + | Mean age >60 years old, female > male |
|
± |
|
+ | Nl | + | - | ↑↑ | ↑ | ↑ |
|
Nl | Nl |
|
Bone marrow biopsy |
| ||
Polycythemia vera[2] |
|
+ | - | - | - | + | Mean age >60 years old |
|
- |
|
± | Nl | + | - | ↑ | ↑↑ | ↑ |
|
|
↑ | ↑ | Bone marrow biopsy |
| ||||
Primary myelofibrosis[3] |
|
+ | - | - | - | + | Mean age >60 years old, male> female |
|
- | + | Nl | + | + |
|
↑/↓ | ↓ | ↓ |
|
|
↑ | ↑ | Bone marrow biopsy |
| ||||
Chronic myeloid leukemia[4] |
|
+ | - | - | - | + | Mean age >50 years old, male> female | History of exposure to: | + | + | Nl | + | - |
|
↑ | ↓ | ↑ |
|
|
↑ | ↑ |
|
Bone marrow biopsy |
| |||
Acute myeloid leukemia[5] |
|
+ | - | - | - | + | Median age of 63 years old |
|
+ | + | Nl | + | + |
|
↑/↓ | ↓ | ↑/↓ |
|
|
↑ | ↑ | NA | Bone marrow examination + clinical manifestation |
| |||
Myelodysplastic syndromes[6] |
|
+ | - | - | -/+ | + | Elderly | Exposure to | +/- | Petechiae, purpura, diffuse erythematous rash | + | Nl | + | + | ↑/↓ | ↓ | ↓ |
|
|
Nl | Nl | NA | Bone marrow examination + clinical manifestation |
| |||
Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings | ||
Familial thrombocytosis[7][8] |
|
+ | - | - | + | - | Rare familial disease, middle age male and female |
|
- | Normal | - | Nl | - | - | - | ↑ | Nl | Nl |
|
|
Nl | Nl | NA | Genetic study |
| ||
Reactive thrombocytosis | Anemia/ |
|
+ | - | - | - | + | Any |
|
- | + | Nl to ↓ | - | - | Depends on the etilogy | ↑ | ↓ | Nl |
|
|
Nl | Nl | NA | Clinical manifestation |
| ||
Infection | Chronic infections |
|
+ | + | - | - | + | Any |
|
+ | ± | Nl to ↓ | - | ± | Depends on the etilogy | ↑ | ↓ | ↑ |
|
|
Nl | Nl |
|
Culture | Depends on the etilogy | ||
Tuberculosis |
|
+ | + | - | - | + | Any |
|
+ |
|
- | Nl | - | - | ↑ | Nl | ↑ |
|
|
Nl | Nl |
|
Clinical manifestation+ culture | ||||
Acute bacterial and viral infections |
|
+ | + | - | - | + | Any |
|
+ |
|
- | Nl | - | - | Depends on the etilogy | ↑ | ↑ |
|
|
Nl | Nl |
|
Clinical manifestation+ culture |
| |||
Inflammation | Vasculitides[10] |
|
+ | + | - | ± | + | Any |
|
+ |
|
+ | Nl | - | - | ↑ | Nl to ↓ | ↑ |
|
|
Nl to ↑ | Nl to ↑ |
|
Clinical manifestation+ culture |
| ||
Acute pancreatitis |
|
+ | + | - | - | + | Any | + |
|
- | Nl to ↓ | - | + | ↑ | Nl to ↓ | ↑ |
|
|
Nl to ↑ | Nl to ↑ |
|
Clinical manifestation |
| ||||
Malignancy[11] |
|
+ | + | - | ± | ± | Any |
|
+ |
|
- | Nl to ↓ | Depends on the type | - |
|
↑ | Nl to ↓ | ↑ |
|
|
Nl to ↑ | Nl to ↑ |
|
Biopsy |
| ||
Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings | ||
Tissue damage | Thermal burns | ↑ | |||||||||||||||||||||||||
Trauma | ↑ | ||||||||||||||||||||||||||
Myocardial infarction | ↑ | ||||||||||||||||||||||||||
Medication | Myelosuppressive agents | ↑ | |||||||||||||||||||||||||
Vincristine | ↑ | ||||||||||||||||||||||||||
Epinephrine, glucocorticoids | ↑ | ||||||||||||||||||||||||||
Interleukin-1B | ↑ | ||||||||||||||||||||||||||
All-trans retinoic acid | ↑ | ||||||||||||||||||||||||||
Thrombopoietin | ↑ | ||||||||||||||||||||||||||
Other | Post-splenectomy or functional asplenia | + |
|
↑ |
|
||||||||||||||||||||||
Allergic reactions | ↑ | ||||||||||||||||||||||||||
Exercise | ↑ | ||||||||||||||||||||||||||
Pseudothrombocytosis | Mixed cryoglobulinemia | ||||||||||||||||||||||||||
Cytoplasmic fragments | |||||||||||||||||||||||||||
Category | Condition | Etiology | Increased megakaryocyte proliferation | Accelerated platelet release | Reduced platelet turnover | Inherited | Acquried | Demography | History | Fever | Appearance | Bleeding | BP | Splenomegaly | Jaundice | Other signs | Plt | HB | WBC | PBS | Bone marrow exam | PT | PTT | Imaging | Gold standard | Associated findings |
References
- ↑ Brière, Jean B (2007). Orphanet Journal of Rare Diseases. 2 (1): 3. doi:10.1186/1750-1172-2-3. ISSN 1750-1172. Missing or empty
|title=
(help) - ↑ Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
- ↑ Tefferi, Ayalew; Lasho, Terra L.; Jimma, Thitina; Finke, Christy M.; Gangat, Naseema; Vaidya, Rakhee; Begna, Kebede H.; Al-Kali, Aref; Ketterling, Rhett P.; Hanson, Curtis A.; Pardanani, Animesh (2012). "One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience". Mayo Clinic Proceedings. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. ISSN 0025-6196.
- ↑ Thompson, Philip A.; Kantarjian, Hagop M.; Cortes, Jorge E. (2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clinic Proceedings. 90 (10): 1440–1454. doi:10.1016/j.mayocp.2015.08.010. ISSN 0025-6196.
- ↑ Rose-Inman, Hayley; Kuehl, Damon (2014). "Acute Leukemia". Emergency Medicine Clinics of North America. 32 (3): 579–596. doi:10.1016/j.emc.2014.04.004. ISSN 0733-8627.
- ↑ Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
- ↑ Ding, J. (2004). "Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin". Blood. 103 (11): 4198–4200. doi:10.1182/blood-2003-10-3471. ISSN 0006-4971.
- ↑ Wiestner, A.; Padosch, S. A.; Ghilardi, N.; Cesar, J. M.; Odriozola, J.; Shapiro, A.; Skoda, R. C. (2000). "Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia". British Journal of Haematology. 110 (1): 104–109. doi:10.1046/j.1365-2141.2000.02169.x. ISSN 0007-1048.
- ↑ Kuter, David J. (1996). "The Physiology of Platelet Production". Stem Cells. 14 (S1): 88–101. doi:10.1002/stem.5530140711. ISSN 1066-5099.
- ↑ Hamblin T, Oscier D (September 1978). "Polyarteritis presenting with thrombocytosis and palliated by plasma exchange". Postgrad Med J. 54 (635): 615–7. PMC 2425233. PMID 82963.
- ↑ Yang, Chen; Jiang, Hui; Huang, Shaozhuo; Hong, Hui; Huang, Xiaowen; Wang, Xiaojie; Liao, Weixin; Wang, Xueyi; Chen, Xuewen; Jiang, Liming (2018). "The prognostic role of pretreatment thrombocytosis in gastric cancer". Medicine. 97 (31): e11763. doi:10.1097/MD.0000000000011763. ISSN 0025-7974.